IP Update | GenomeWeb

IP Update


Title: Method of Treating Neurodegenerative Disease

Number: 7,595,306

Filed: Oct. 12, 2006

Inventor: David Bumcrot, Alnylam Pharmaceuticals

"Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein gene expression, such as for the treatment of neurodegenerative disorders," the patent's abstract states. "An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.